8-K - Centessa Pharmaceuticals plc | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Centessa Pharmaceuticals entered into an Advisory Agreement and a Separation Agreement with former CEO Saurabh Saha, effective February 9, 2026, following his departure on January 1, 2026. The agreements establish advisory compensation at $376.00 per hour and provide for equity vesting and a 100% target bonus payment for 2025.

Key Takeaways

1Saurabh Saha stepped down as CEO and Board member effective January 1, 2026.

2The Company entered into an Advisory Agreement and Separation Agreement with Dr. Saha on February 9, 2026.

3Dr. Saha will receive an hourly advisory fee of $376.00 for an initial six-month period.

4Equity grants due to vest on or prior to February 2, 2026 will vest; equity due to vest after that date is forfeited.

5Dr. Saha is eligible for a bonus payment equal to 100% of his target bonus for the year ended December 31, 2025, subject to Compensation Committee approval.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously

Management Change

$376.00

Executive & Director Changes

Saurabh Saha, M.D., Ph.D.

Chief Executive Officer and member of the Board of Directors

Departure and Appointment as Advisor

Effective: 2026-01-01

Not disclosed

Transaction Details

Material Agreement

Exhibits (1)

8-K